Detailed results from the phase 3 TEMPO trials show tavapadon offers a mechanistically distinct approach for managing motor ...
NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results